Figure S1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
John D. Powderly, Martina Imbimbo, Antoîne Italiano, Patricia Martín-Romano et autres
Study Design
0 citations
Chunling Fan
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
34Publications signalées
125Citations signalées
1Affiliations récentes
Les institutions déclarées
Les domaines associés
Monoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer ResearchCAR-T cell therapy researchAnesthesia and Pain ManagementVirus-based gene therapy research
Les publications récentes
Data from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
John D. Powderly, Martina Imbimbo, Antoîne Italiano, Patricia Martín-Romano et autres
AbstractPurpose: Blocking enzymatic activity of cluster of differentiation 39 (CD39) with IPH5201 may promote antitumor immunity by increasing immunostimulatory ATP and reducing immunosuppressive adenosine levels in the tumor microenvironment. This first-in-human, phase 1 study evaluated IPH5201 as monotherapy or in combination with …
0 citations
Table S1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
John D. Powderly, Martina Imbimbo, Antoîne Italiano, Patricia Martín-Romano et autres
TEAEs of any grade occurring in >10% of all patients.
0 citations
Table 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
John D. Powderly, Martina Imbimbo, Antoîne Italiano, Patricia Martín-Romano et autres
Patient characteristicsa.
0 citations
Figure 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
John D. Powderly, Martina Imbimbo, Antoîne Italiano, Patricia Martín-Romano et autres
Mean (± SD) serum concentration of IPH5201 across dose cohorts and treatment. Data are shown based on the PK analysis set, defined as patients who received ≥1 dose of IPH5201 or durvalumab (durva) and provided ≥1 quantifiable posttreatment sample. Vertical lines represent …
0 citations
Figure 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
John D. Powderly, Martina Imbimbo, Antoîne Italiano, Patricia Martín-Romano et autres
Best change in tumor size from baseline for (A) IPH5201 monotherapy (n = 38) and (B) IPH5201 + durvalumab (n = 19). Patients who developed new lesion as defined per RECIST v1.1 are denoted by an asterisk (*). Data are shown based …
0 citations
Table 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
John D. Powderly, Martina Imbimbo, Antoîne Italiano, Patricia Martín-Romano et autres
Summary of efficacya.
0 citations
Table 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
John D. Powderly, Martina Imbimbo, Antoîne Italiano, Patricia Martín-Romano et autres
Safety summarya.
0 citations
Table S4 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
John D. Powderly, Martina Imbimbo, Antoîne Italiano, Patricia Martín-Romano et autres
IPH5201 PK Parameters following a single dose of intravenous IPH5201.
0 citations
Figure 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
John D. Powderly, Martina Imbimbo, Antoîne Italiano, Patricia Martín-Romano et autres
IPH5201 treatment decreases tumoral CD39 enzymatic activity. The Wachstein–Meisel assay detects the presence of phosphates hydrolyzed from ATP due to enzymatic activity of CD39. A, Representative histology images of tumor tissues with reduction in CD39 enzymatic activity after treatment with IPH5201. B, …
0 citations
Supplementary Appendix from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
John D. Powderly, Martina Imbimbo, Antoîne Italiano, Patricia Martín-Romano et autres
Supplementary Appendix and Study Representativeness Figure
0 citations
Table S3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
John D. Powderly, Martina Imbimbo, Antoîne Italiano, Patricia Martín-Romano et autres
TEAEs of special interest for IPH5201: thromboembolic events.
0 citations
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.